Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE: Durvalumab + Tremelimumab vs SoC in First-Line Advanced/Metastatic NSCLC
NCT02542293Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Sep 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 29
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2015; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02542293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542293.